구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | atezolizumab (Tecentriq, Atezolizumab and Recombinant Human Hyaluronidase) Roche / Genentech·Lung Non-Small Cell Carcinoma 7 trials |
|---|---|
Overview Program | Atezolizumab and Recombinant Human Hyaluronidase |
Overview Company | Roche / Genentech |
Overview Modality | ANTIBODY |
Overview Target | Lung Non-Small Cell Carcinoma |
Overview Indication | Lung Non-Small Cell Carcinoma; Stage II Lung Cancer AJCC v8 |
Overview Phase | PHASE_3 |
Overview Status | RECRUITING |
Overview Content status | Limited Data |
Overview Data Confidence | Data Confidence · Low |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
PK/PD Animal (cat.) | Unknown |
PK/PD Experiment | pharmacokinetic |
Toxicology Animal (cat.) | Unknown |
Toxicology Major finding | IMscin001 Part 2: a randomised phase III, open-label, multicentre study examining the pharmacokinetics, efficacy, immunogenicity, and safety of atezolizumab subcutaneous versus intravenous administration in previously treated locally advanced or metastatic non-small-cell lung cancer and pharmacokinetics comparison with other approved indications.. Atezolizumab intravenous (IV) is approved for the … |
Clinical Safety signal | IMscin001 Part 2: a randomised phase III, open-label, multicentre study examining the pharmacokinetics, efficacy, immunogenicity, and safety of atezolizumab subcutaneous versus intravenous administration in previously treated locally advanced or metastatic non-small-cell lung cancer and pharmacokinetics comparison with other approved indications.. Atezolizumab intravenous (IV) is approved for the … |
Clinical Selected reported efficacy | ORR 10.5% |
Clinical Reported ORR | 10.5% |
Clinical Reported PFS | 2.9 |
Clinical Reported OS | 10.1 |
Clinical Result source | ClinicalTrials.gov NCT03735121 |
Clinical Program phase | PHASE_3 |
Clinical Trial ref | NCT03735121 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | atezolizumab (Tecentriq, Atezolizumab and Recombinant Human Hyaluronidase) Roche / Genentech·Lung Non-Small Cell Carcinoma 7 trials |
|---|---|
Overview Program | Atezolizumab and Recombinant Human Hyaluronidase |
Overview Company | Roche / Genentech |
Overview Modality | ANTIBODY |
Overview Target | Lung Non-Small Cell Carcinoma |
Overview Indication | Lung Non-Small Cell Carcinoma; Stage II Lung Cancer AJCC v8 |
Overview Phase | PHASE_3 |
Overview Status | RECRUITING |
Overview Content status | Limited Data |
Overview Data Confidence | Data Confidence · Low |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
PK/PD Animal (cat.) | Unknown |
PK/PD Experiment | pharmacokinetic |
Toxicology Animal (cat.) | Unknown |
Toxicology Major finding | IMscin001 Part 2: a randomised phase III, open-label, multicentre study examining the pharmacokinetics, efficacy, immunogenicity, and safety of atezolizumab subcutaneous versus intravenous administration in previously treated locally advanced or metastatic non-small-cell lung cancer and pharmacokinetics comparison with other approved indications.. Atezolizumab intravenous (IV) is approved for the … |
Clinical Safety signal | IMscin001 Part 2: a randomised phase III, open-label, multicentre study examining the pharmacokinetics, efficacy, immunogenicity, and safety of atezolizumab subcutaneous versus intravenous administration in previously treated locally advanced or metastatic non-small-cell lung cancer and pharmacokinetics comparison with other approved indications.. Atezolizumab intravenous (IV) is approved for the … |
Clinical Selected reported efficacy | ORR 10.5% |
Clinical Reported ORR | 10.5% |
Clinical Reported PFS | 2.9 |
Clinical Reported OS | 10.1 |
Clinical Result source | ClinicalTrials.gov NCT03735121 |
Clinical Program phase | PHASE_3 |
Clinical Trial ref | NCT03735121 |
추천 비교
추천 비교